NBIX - Neurocrine Biosciences, Inc.
NEXT EARNINGS:
May 4, 2026
EPS Est: $1.66
|
Rev Est: $771.2M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$168.46
DETAILS
HIGH:
$192.00
LOW:
$140.00
MEDIAN:
$174.00
CONSENSUS:
$168.46
UPSIDE:
28.63%
Market Cap:
13.14B
Volume:
955,199
Avg Volume:
1,128,543
52 Week Range:
84.23-160.18
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
0.31
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
1,800
IPO Date:
1996-05-23
EPS (TTM):
4.81
P/E Ratio:
29.49
Revenue (TTM):
2.86B
Total Assets:
4.63B
Total Debt:
415.30M
Cash & Equiv:
713.00M
Rev Growth (5Y):
22.3%
EPS Growth (5Y):
1.9%
FCF Growth (5Y):
28.0%
ROCE:
16.4%
Debt/Equity:
0.13
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-11 | $1.88 | $2.25 | -16.4% | $805.5M | $775.6M | +3.9% |
| 2025-10-28 | $2.04 | $1.58 | +29.1% | $794.9M | $806.8M | -1.5% |
| 2025-07-30 | $1.06 | $0.98 | +8.2% | $687.5M | $746.4M | -7.9% |
| 2025-05-05 | $0.08 | $0.54 | -85.0% | $572.6M | $559.6M | +2.3% |
| 2025-02-06 | $1.00 | $1.62 | -38.3% | $627.7M | $629.4M | -0.3% |
| 2024-10-30 | $1.24 | $1.51 | -17.9% | $622.1M | $600.6M | +3.6% |
| 2024-08-01 | $0.63 | $1.05 | -40.0% | $590.2M | $545.9M | +8.1% |
| 2024-05-01 | $0.42 | $1.01 | -58.4% | $515.3M | $512.4M | +0.6% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.86B | 2.36B | 1.89B | 1.49B | 1.13B | 1.05B | 788.10M | 451.20M | 161.63M | 15.00M | 19.77M | 0 |
| Net Income | 478.60M | 341.30M | 249.70M | 154.50M | 89.60M | 407.30M | 37.00M | 21.11M | (142.54M) | (141.09M) | (88.93M) | (60.54M) |
| EPS | 4.81 | 3.40 | 2.56 | 1.61 | 0.95 | 4.37 | 0.40 | 0.22 | -1.62 | -1.63 | -1.05 | -0.81 |
| Total Assets | 4.63B | 3.72B | 3.25B | 2.37B | 2.07B | 1.73B | 1.31B | 993.15M | 817.59M | 365.09M | 474.79M | 243.03M |
| Total Debt | 415.30M | 455.10M | 428.40M | 262.90M | 440.40M | 412.30M | 495.50M | 388.50M | 369.62M | 0 | 0 | 0 |
| Cash & Equivalents | 713.00M | 233.00M | 251.10M | 262.90M | 340.80M | 187.10M | 112.30M | 141.71M | 254.71M | 83.27M | 74.19M | 31.01M |
| Operating Cash Flow | 782.70M | 595.40M | 389.90M | 339.40M | 256.50M | 228.50M | 147.00M | 101.40M | (94.33M) | (106.18M) | (38.00M) | (47.14M) |
| Free Cash Flow | 748.70M | 557.20M | 361.60M | 322.90M | 233.10M | 217.60M | 132.30M | 76.60M | (101.27M) | (110.29M) | (39.93M) | (48.75M) |
| FCF per Share | 7.52 | 5.55 | 3.70 | 3.37 | 2.46 | 2.34 | 1.44 | 0.80 | -1.15 | -1.27 | -0.47 | -0.65 |
| Book Value | 3.25B | 2.59B | 2.23B | 1.71B | 1.37B | 1.13B | 636.90M | 480.76M | 372.14M | 314.88M | 424.45M | 208.70M |
| Cash & ST Investments | 1.48B | 1.08B | 1.03B | 989.30M | 711.30M | 801.00M | 670.50M | 650.91M | 515.93M | 307.35M | 379.19M | 193.81M |
| ROC Equity | 0.15 | 0.13 | 0.11 | 0.09 | 0.07 | 0.36 | 0.06 | 0.04 | -0.38 | -0.45 | -0.21 | -0.29 |